论文部分内容阅读
目的:分析探讨小剂量和标准剂量美常安对溃疡性结肠炎(UC)患者维持治疗的临床疗效及安全性。方法:选取2015年1月至2016年1月我院收治的UC缓解期患者共93例,将其随机平均分配为3组,A组31例,B组31例,C组31例。A组采用美沙拉嗪缓释颗粒进行治疗,B组采用美常安进行小剂量口服治疗,C组采用美常安进行标准剂量口服治疗。对全部患者进行6个月随访,对比3组维持缓解时间,以及不良反应发生情况。同时对全部患者行肠镜复查,对UC活动度积分,以及病理组织学积分进行记录。结果:三组患者的维持缓解时间,UC复发率,以及肠镜活动度积分,病理组织学积分差异均无统计学意义(P>0.05)。结论:对于UC缓解期患者采用小剂量美常安进行治疗是有效且安全的,值得在临床上推广应用。
Objective: To investigate the clinical efficacy and safety of low-dose and standard-dose metoclopramide in the maintenance of patients with ulcerative colitis (UC). Methods: A total of 93 patients with UC remission admitted in our hospital from January 2015 to January 2016 were randomly assigned to three groups, including 31 cases in group A, 31 cases in group B and 31 cases in group C. A group treated with mesalazine sustained-release particles for treatment, B group using the United States and the United States for small doses of oral treatment, C group with the United States for the standard dose of oral treatment. All patients were followed up for 6 months, compared with the three groups to maintain remission, and adverse reactions. At the same time, all patients underwent colonoscopy, the score of UC activity, and histopathological score were recorded. Results: There was no significant difference between the three groups in maintaining remission time, recurrence rate of UC, and score of enteroscopy activity and histopathological score (P> 0.05). Conclusions: It is effective and safe to treat patients with remission stage with low dosage of methotrexate, so it is worth popularizing in clinic.